Danger Reduced India’s network of government-funded Covid genome sequencing labs said in late November that boosters should be considered for over-40s and those at high risk, as the danger of severe disease will likely be reduced.
India’s drug regulator has so far been reluctant to authorize third doses or childhood vaccinations until local trial data has been produced.
Government officials have been reiterating targets to fully inoculating the country’s adult population first. India’s health ministry didn’t immediately respond to a request for comment.
While the head of the Serum Institute of India Ltd. -- which is locally producing the AstraZeneca shots -- warned of a production drop two weeks ago due to lack of orders, Shaw expects